 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2526272829303132333435...208209» |
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed: A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices (clinicaltrials.gov) - Aug 22, 2025
P1, N=51, Active, not recruiting, Sponsor: Kailera
Not yet recruiting --> Active, not recruiting
- ||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial completion: PHEDRA: Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (clinicaltrials.gov) - Aug 22, 2025
P3, N=355, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial suspension: CamPacBTC: Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study (EUDRACT) - Aug 22, 2025
P=N/A, N=63, Suspended, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
Active, not recruiting --> Completed Recruiting --> Suspended
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Trial initiation date: An open-label, parallel-cohort, multicenter clinical study of Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (EUDRACT) - Aug 22, 2025
P4, N=100, Not yet recruiting, Sponsor: The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
Recruiting --> Suspended Initiation date: Dec 2024 --> Apr 2025
- | Preclinical, Journal, PD(L)-1 Biomarker: NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report. (Pubmed Central) - Aug 22, 2025
Initiation date: Dec 2024 --> Apr 2025 Prior treatments included the first-line therapy gefitinib (250
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer. (Pubmed Central) - Aug 22, 2025
Prior treatments included the first-line therapy gefitinib (250 Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Enrollment open: A Phase II clinical study of SHR-1701 combined with albumin paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion (EUDRACT) - Aug 22, 2025
P=N/A, N=42, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion: Camoral: A multicenter, open, randomized controlled phase II clinical trial of chemotherapy combined with Camrelizumab in the perioperative treatment of locally advanced head and neck squamous cell carcinoma (EUDRACT) - Aug 22, 2025
P2, N=125, Completed, Sponsor: Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University Scho
Not yet recruiting --> Recruiting Recruiting --> Completed
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment closed: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (clinicaltrials.gov) - Aug 21, 2025
P2, N=30, Active, not recruiting, Sponsor: Harbin Medical University
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
New P2 trial: Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Aug 21, 2025
P2, N=55, Not yet recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- | AiTan (rivoceranib) / HLB Bio Group, temozolomide / Generic mfg.
Retrospective data, Journal: Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. (Pubmed Central) - Aug 21, 2025
Follow-up results showed that the Combination group had a significantly better overall survival (OS) and progression-free survival (PFS) than the Control group. Compared with temozolomide alone, apatinib plus tenozolomide can significantly improve the clinical efficacy in treating recurrent malignant brain glioma, prolong the survival of patients and produce tolerable adverse reactions.
- || Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies, Airuituo (bevacizumab biosimilar) / Jiangsu Hengrui Pharma
Clinical, P2 data, Journal: Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. (Pubmed Central) - Aug 21, 2025
P2
This treatment approach warrants further validation in a randomized clinical trial. ClinicalTrials.gov Identifier: NCT05357417.
- || HRS-5965 / Jiangsu Hengrui Pharma
Trial completion: Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects (clinicaltrials.gov) - Aug 20, 2025
P1, N=36, Completed, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT05357417. Active, not recruiting --> Completed
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) - Aug 20, 2025
P2, N=84, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- || HRS-5965 / Jiangsu Hengrui Pharma
Trial completion: A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects (clinicaltrials.gov) - Aug 20, 2025
P1, N=16, Completed, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Completed
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
New P2 trial: HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov) - Aug 20, 2025
P2, N=30, Not yet recruiting, Sponsor: Ruijin Hospital
- |||||||||| GSK5784283 / GSK
New P3 trial: Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - Aug 20, 2025
P3, N=280, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- | oxaliplatin / Generic mfg., Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer. (Pubmed Central) - Aug 20, 2025
Not yet recruiting --> Completed This translational study suggests that pyrotinib combined with oxaliplatin may serve as a promising strategy for patients with EGFR-high copy number gastric cancer and highlighted the discovery of this previously unknown EGFR/ GRP78 signaling axis, which provides the molecular basis and the rationale to target EGFR.
- ||||| Xiidra (lifitegrast) / Bausch Health, NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
New P2 trial: A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (clinicaltrials.gov) - Aug 20, 2025
P2, N=423, Not yet recruiting, Sponsor: Bausch & Lomb Incorporated
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response (clinicaltrials.gov) - Aug 19, 2025
P2, N=30, Not yet recruiting, Sponsor: Chuan Wang
- || SHR7280 / Jiangsu Hengrui Pharma
Trial completion: A Trial of SHR7280 in Healthy Subjects (clinicaltrials.gov) - Aug 19, 2025
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This translational study suggests that pyrotinib combined with oxaliplatin may serve as a promising strategy for patients with EGFR-high copy number gastric cancer and highlighted the discovery of this previously unknown EGFR/ GRP78 signaling axis, which provides the molecular basis and the rationale to target EGFR. Not yet recruiting --> Completed
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma, Perjeta (pertuzumab) / Roche
New P2 trial: Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer (clinicaltrials.gov) - Aug 19, 2025
P2, N=63, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
Tegileridine for Postoperative Pain Management in Abdominal Surgery: A Randomized, Double-Blind, Phase 3 Clinical Trial [WITHDRAWN] (221D, Meeting Level) - Aug 19, 2025 - Abstract #ASA2025ASA_4346;
Not yet recruiting --> Completed Abstract is embargoed at this time.
- |||| sonesitatug vedotin (AZD0901) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy: CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - Aug 18, 2025
P3, N=572, Recruiting, Sponsor: AstraZeneca
Abstract is embargoed at this time. Trial completion date: Oct 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Real-world evidence: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 18, 2025
P=N/A, N=240, Recruiting, Sponsor: Sun Yat-sen University
Trial completion date: Oct 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Oct 2026 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, pMMR: Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) (clinicaltrials.gov) - Aug 18, 2025
P2, N=90, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 N=162 --> 90
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New trial: Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 18, 2025
P=N/A, N=20, Enrolling by invitation, Sponsor: Zhujiang Hospital
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P3 trial: PICASSO: PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis (clinicaltrials.gov) - Aug 18, 2025
P3, N=5276, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- |||||||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 18, 2025
P3, N=600, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - Aug 18, 2025
P3, N=400, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||||||| Xiidra (lifitegrast) / Bausch Health, NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
New P3 trial: NGL-Long Term: A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease (clinicaltrials.gov) - Aug 18, 2025
P3, N=150, Not yet recruiting, Sponsor: Bausch & Lomb Incorporated
- | Hetronifly (serplulimab) / Alvogen, Shanghai Henlius Biotech
New P3 trial: A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 18, 2025
P3, N=435, Not yet recruiting, Sponsor: Tao Zhang
- | zeprumetostat (SHR-2554) / Treeline Biosci
New P2 trial: SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer (clinicaltrials.gov) - Aug 18, 2025
P2, N=60, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | New P2 trial: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (clinicaltrials.gov) - Aug 18, 2025
P2, N=20, Not yet recruiting, Sponsor: Fudan University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov) - Aug 18, 2025
P2, N=36, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- ||| HRS-9821 / GSK
New P1 trial: A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (clinicaltrials.gov) - Aug 18, 2025
P1, N=82, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - Aug 18, 2025
P2, N=45, Recruiting, Sponsor: Fudan University
N=162 --> 90 Not yet recruiting --> Recruiting
- | Enrollment open: LEAF-02: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab (clinicaltrials.gov) - Aug 18, 2025
P2, N=141, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| CS1002 (ipilimumab biosimilar) / CStone Pharma
Enrollment open: A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov) - Aug 18, 2025
P2, N=200, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| IDE849 / Ideaya Biosci
Enrollment open: A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - Aug 18, 2025
P2, N=120, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Journal, BRCA Biomarker, PARP Biomarker: A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments. (Pubmed Central) - Aug 18, 2025
Through comprehensive analysis of gene mutation profiles (KIT and HRR gene mutations, including BRCA2), a combination therapy of fluzoparib, pamiparib, and ripretinib was administered, stabilizing the patient's condition with significant efficacy. This case highlights the importance of genetic testing and personalized targeted treatment strategies for gastrointestinal stromal tumor (GIST) patients.
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Aug 16, 2025
P3, N=200, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This case highlights the importance of genetic testing and personalized targeted treatment strategies for gastrointestinal stromal tumor (GIST) patients. Not yet recruiting --> Recruiting
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: A Phase 1, single ascending dose study in healthy, overweight and obese participants to investigate safety, tolerability and pharmacokinetics of KAI-9531 subcutaneous injection (EUDRACT) - Aug 14, 2025
P1, N=50, Completed, Sponsor: Kailera Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- AiRuiKa (camrelizumab) / HLB Bio Group
A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC (Room 06) - Aug 14, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2887;
P2
Although durvalumab consolidation has enhanced outcomes compared to traditional concurrent chemoradiotherapy (CRT), disease progression remains a formidable challenge...Patients were randomly assigned (1:1) to either an experimental regimen of induction immunotherapy and chemotherapy (two cycles of camrelizumab plus etoposide-platinum [EP] or etoposide-carboplatin [EC]) followed by CRT, prophylactic cranial irradiation (PCI), and up to 12 months of camrelizumab consolidation (camrelizumab group), or a control regimen of induction chemotherapy (EP or EC) followed by CRT and PCI (cCRT group)...Conclusions : These findings suggest that induction camrelizumab plus chemotherapy followed by CRT and camrelizumab consolidation may improve both PFS and OS in LS-SCLC without exacerbating toxicity. Further research to refine treatment sequencing could provide vital improvements in managing this challenging disease.
- | SHR-1501 / Jiangsu Hengrui Pharma
Biomarker, Journal: IL-15 Superagonist SHR-1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment. (Pubmed Central) - Aug 13, 2025
Its mechanism likely involves promoting CD8+ T cell and NK cell infiltration and enhancing M1 macrophage activity. These findings provide evidence for further clinical trials exploring SHR-1501 in nonsmall cell lung cancer (NSCLC) therapy.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
Journal: Targeted Therapy with Dalpiciclib in a Pediatric Patient with Anaplastic Ependymoma: A Case Study and Literature Review. (Pubmed Central) - Aug 13, 2025
This report represents the first use of the CDK4/6 inhibitor Dalpiciclib for the treatment of anaplastic ependymoma. The treatment was guided by insights from next-generation sequencing (NGS) analysis and has shown promising results in terms of patient survival.
- || SHR-1707 / Jiangsu Hengrui Pharma
Trial completion: Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients. (clinicaltrials.gov) - Aug 12, 2025
P1, N=33, Completed, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
The treatment was guided by insights from next-generation sequencing (NGS) analysis and has shown promising results in terms of patient survival. Active, not recruiting --> Completed
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Rituxan (rituximab) / Roche
Journal: A Patient With Three Types of Hematologic Disorders and Hemophagocytic Lymphohistiocytosis Triggered by SARS-CoV-2: A Case Report. (Pubmed Central) - Aug 12, 2025
This case underscores the importance of monitoring immune depression and subsequent malignancies as more patients achieve long-term survival with hematologic cancers due to evolving therapeutic advances. Early recognition and adequate supportive therapies are crucial, especially in managing elderly patients with malignancies.
- | AiTan (rivoceranib) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Apatinib-loaded silicate nanoparticles coated with macrophage membranes and PD-1 antibody for enhanced chemo-immunotherapy in ovarian cancer via VEGFR2 and PD-1 dual inhibition. (Pubmed Central) - Aug 11, 2025
levels. This study provides a promising multi-modal strategy for overcoming challenges in cancer therapy by integrating chemotherapy, immunotherapy, and targeted drug delivery, offering potential for improved treatment outcomes in ovarian cancer.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group, VRT106 / Guangzhou Virotech
Journal: Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. (Pubmed Central) - Aug 11, 2025
P1
This study provides a promising multi-modal strategy for overcoming challenges in cancer therapy by integrating chemotherapy, immunotherapy, and targeted drug delivery, offering potential for improved treatment outcomes in ovarian cancer. The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.